2055990-82-2
2055990-82-2
Chemical Structure
CCG 224061
- No. CAS: 2055990-82-2
- Formula:C19H20FN3O
- Molecular Weight:325.39
IUPAC Name: 5-(((3S,4R)-4-(4-fluorophenyl)piperidin-3-yl)methoxy)-1H-indazole
InChIKey: ICFQMYOLILBYFP-YJBOKZPZSA-N
SMILES: C(OC=1C=C2C(=CC1)NN=C2)[C@H]3[C@@H](CCNC3)C4=CC=C(F)C=C4
Biological Activity: CCG 224061 is a G protein-coupled receptor kinase 2 (GRK2) inhibitor with a IC50 of 0.066 μM. CCG 224061 inhibits GRK activity in cardiomyocytes[1]. CCG 224061 is applicable to research related to heart disease, heart failure, myocardial hypertrophy and hypertension[1][2].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CCG 224061 | CCG 224061 is a G protein-coupled receptor kinase 2 (GRK2) inhibitor with a IC50 of 0.066 μM. CCG 224061 inhibits GRK activity in cardiomyocytes. CCG 224061 is applicable to research related to heart disease, heart failure, myocardial hypertrophy and hypertension. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Scott D. Larsen, et al. G protein-coupled receptor kinase inhibitors and methods for use of the same. WO2016210403A1. 2017-12-26.
- [2]. Bouley R, et al. Structural Determinants Influencing the Potency and Selectivity of Indazole-Paroxetine Hybrid G Protein-Coupled Receptor Kinase 2 Inhibitors. Mol Pharmacol. 2017;92(6):707-717. [Content Brief]
Keywords
